Related Experiment Video

Updated: Jun 25, 2026

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

Unfractionated heparin therapy in infants and children

Fiona Newall1, Linda Johnston, Vera Ignjatovic

  • 1MN, BSci, Royal Children's Hospital, Clinical Haematology Department, 9th Floor, Main Building, Flemington Road, Parkville, Victoria 3052, Australia. fiona.newall@rch.org.au

Pediatrics
|February 18, 2009
PubMed

Insights

Unfractionated heparin use in children has poor outcomes due to age-related effects and flawed monitoring. Pediatric-specific guidelines are needed for safer and more effective heparin therapy.

Area of Science:

  • Pediatric pharmacology
  • Thromboembolic disease management
  • Anticoagulant therapy

Background:

  • Unfractionated heparin is a common treatment for pediatric thromboembolic disease.
  • Current unfractionated heparin therapy in children is associated with suboptimal clinical outcomes.
  • Potential age-dependent mechanisms and limitations in monitoring assays contribute to these poor outcomes.

Purpose of the Study:

  • To review the evidence on the efficacy and safety of unfractionated heparin in pediatric patients.
  • To highlight the limitations of current unfractionated heparin monitoring assays in children.
  • To advocate for the development of pediatric-specific recommendations for unfractionated heparin management.

Main Methods:

  • Literature review of published studies on unfractionated heparin in pediatric populations.
  • Analysis of data regarding target-range achievement and adverse events.
  • Evaluation of unfractionated heparin monitoring assay performance in children.

Main Results:

  • Evidence suggests poor clinical outcomes in children receiving unfractionated heparin.
  • Target-range achievement is frequently suboptimal, and adverse events are a concern.
  • Current monitoring assays demonstrate significant limitations in accurately assessing unfractionated heparin levels in pediatric patients.

Conclusions:

  • Pediatric patients may respond differently to unfractionated heparin compared to adults.
  • Existing monitoring methods are inadequate for optimizing pediatric unfractionated heparin therapy.
  • Development of pediatric-specific guidelines and improved monitoring strategies is crucial for enhancing patient safety and treatment efficacy.

More Related Videos

Guidelines for Elective Pediatric Fiberoptic Intubation11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...